Zydus Cadila gets US FDA tentative marketing nod for epilepsy drug, brivaracetam

Last edition

Zydus Cadila gets US FDA tentative marketing nod for epilepsy drug, brivaracetam

Zydus Cadila has received tentative approval from the US FDA to market brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.

Brivaracetam is used to treat partial-onset of seizures (epilepsy).

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Read more on:
US FDA tentative marketing nod for epilepsy drug, Zydus Cadila gets US FDA tentative marketing nod f

More news about: biotechnology | Published by Darshana | June - 14 - 2021 | 145

Last news about this category

Bio-Techne Expands Partnership with Leica Biosystems to Advance Spatial Biology Research

AMSBIO Now Offers Ethically Sourced Range of Human Blood Biospecimens for Research

IPA and RIBOPRO to Advance mRNA-Driven Antibody Discovery

IIT Guwahati Signs MoU with K.N. Bioscience for C-Phycocyanin Production Technology

Abzena Expands its Microbiology Laboratory Space for Biologic Manufacturing

Duke Street Bio Gets EMA Approval to Launch PARP1-Selective Inhibitor Trial

Indian Govt Approves Bio-RIDE Scheme to Accelerate R&D in Biotechnology

NATCO Pharma Announces Investment of USD 8 Million in eGenesis

EUROAPI and Priothera to Advance Oncology Project

Northwest Biotherapeutics Bags Exclusive In-License of Dendritic Cell Technology

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy